Heart health and weight medicines: reading the evidence

Start with your own clinical situation

Established vascular disease, heart failure and an increased future risk are different circumstances. Ask which actually applies to you. Existing diagnoses and reports are more helpful than a broad promise of “heart protection”. Bring your latest clinical letter and medication list. This allows the conversation to start with your situation rather than the most striking headline or an assumption that all heart conditions require the same approach.

What SELECT studied

SELECT included 17,604 people aged 45 or older with cardiovascular disease, BMI at least 27 and no diabetes. Over an average 39.8 months, the combined endpoint occurred in 6.5% with semaglutide and 8.0% with placebo.

The endpoint combined cardiovascular death, nonfatal heart attack or nonfatal stroke. It brings different events together. A benefit for that combination should not be described as an identical benefit for each component. Nor does the trial automatically answer whether healthy people of normal weight should be treated. The starting population is an essential part of the result.

Keep numbers in context

The observed proportions differ by 1.5 percentage points: mathematically, 15 fewer events per 1,000 participants over the stated period. This is not a prediction for you. The often-quoted 20% relative reduction refers to the time-based hazard ratio of 0.80. It does not mean 20 percentage points or 20% fewer deaths. Different statistical descriptions should not be substituted for one another without explaining what they measure.

Heart failure is a different research question

HFpEF is heart failure with preserved ejection fraction. In 2026, EMA assessed tirzepatide data in people with HFpEF and obesity. It added findings to the product information but did not recommend a separate HFpEF indication. Fewer hospital admissions must be distinguished from an established reduction in cardiovascular deaths.

Do not turn one study into a ranking of all weight medicines. Different conditions, products and measurements may answer different questions. Ask which finding is relevant to your care instead of assuming that any favourable cardiovascular headline settles the choice.

Consider authorisation alongside treatment

The EU overviews checked list weight management for Wegovy and Mounjaro, and type 2 diabetes for Mounjaro. Research findings or United States approval announcements do not establish an additional blanket EU heart indication. Ask about the specific reason for treatment and expected benefits relative to burdens. Weight treatment does not replace follow-up or existing heart medicines. Any changes belong in a coordinated clinical plan.

Prepare questions and recognise urgent situations

For a routine appointment, three questions help: which outcome are we trying to improve? How large might the benefit be in my situation? Which checks and adverse effects need consideration? New severe chest pressure or pain, severe breathing difficulty or unconsciousness instead requires immediate emergency medical help. Do not wait for a comment reply or for an explanation of the next research article in that situation.